Cardiff Oncology Settles Nerviano License Dispute, Amends Onvansertib Agreement
CRDF sits 64% above its 52-week low of $0.757.
Summary
Cardiff Oncology settled its litigation with Nerviano Medical Sciences and amended the 2017 license agreement for onvansertib, removing a major legal overhang while adding new milestone and change-of-control payment obligations.
Key Events · Legal and Risk Events · CRDF
-
License Dispute Settled
Cardiff Oncology and Nerviano Medical Sciences entered into a Confidential Settlement Agreement and Release on September 14, 2026, resolving all claims in the litigation over inventorship and performance under the 2017 license agreement for onvansertib. No monetary payment was made by either party.
-
License Agreement Amended
The parties executed an Amendment to License Agreement with material new terms, including an updated exclusivity framework, an additional license fee on Cardiff patents, development milestone and performance-related payment obligations tied to the Phase 3 program, revised post-termination royalty tiers, and a revised assignment provision requiring a percentage of transaction proceeds if Cardiff is acquired before Phase 3 data readout.
-
Nerviano Gains Governance Rights
Nerviano receives a board observer seat and a seat on Cardiff's Scientific Advisory Board, along with enhanced governance, reporting, and Joint Development Committee provisions for onvansertib development.
-
Termination Protections Strengthened
The amended agreement requires a judicial or arbitral determination of material breach before termination for cause, and adds automatic termination events tied to bankruptcy, cessation of operations, or 90 consecutive days of inactivity on onvansertib.
Analysis · CRDF · Life Sciences
Cardiff Oncology resolved its existential license dispute with Nerviano Medical Sciences over onvansertib, its lead drug candidate. The settlement removes a major legal overhang that threatened the company's core asset. The amended license agreement adds new financial obligations — including development milestone payments tied to the upcoming Phase 3 program and a percentage of transaction proceeds if Cardiff is acquired before Phase 3 data readout — but also strengthens exclusivity and provides Nerviano with board observer and Scientific Advisory Board seats. No cash changed hands in the settlement itself, but the new terms reshape Cardiff's long-term economics and governance around onvansertib.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CRDF was trading at $1.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $94.1M. The 52-week trading range was $0.76 to $3.31. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.